R-CHOP Regimen Underused in Elderly DLBCL Patients

News
Article

Despite an association with improved survival, elderly DLBCL patients are less likely to receive standard-of-care chemotherapy with R-CHOP.

Patients with diffuse large B-cell lymphoma (DLBCL) aged older than 80 years were significantly less likely to receive standard-of-care chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) compared with younger patients, according to the results of a recent study.

However, R-CHOP was the only chemotherapy regimen associated with an increased overall survival and lymphoma-related survival among this patient population.

“These findings indicate that very elderly patients with DLBCL who can tolerate R-CHOP should be treated with this regimen,” wrote researchers led by Jessica N. Williams, BS, of Emory University School of Medicine in Atlanta. “Clinicians should consider functional status and comorbidities when making treatment decisions for individual patients.”

The researchers looked at presentation, treatment, and survival in a group of 4,635 patients with DLBCL taken from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Of these patients, 1,156 (25%) were aged older than 80 years.

Treatment patterns showed that patients aged older than 80 were significantly more likely to be recommended for observation and were less likely to receive CHOP or R-CHOP regimens when compared with patients aged 66 to 80 (P < .0001 for both).

“However, approximately 25% of patients aged > 80 years had no initial therapy recorded within the 6 months after diagnosis,” the researchers wrote in Cancer. “This is somewhat surprising because less than 50% had a poor performance status and only 20% had a comorbidity score > 1.”

Data showed an increased likelihood of receiving R-CHOP in patients aged older than 80 who were married, had stage III/IV disease, and had received radiotherapy or growth factor therapy.

“These results suggest that the failure of very elderly patients with DLBCL to receive standard treatment is associated with clinical factors, but also may vary across demographic factors such as marital status,” the researchers noted.

The researchers found that treatment with R-CHOP was the only regimen associated with an increased overall survival (hazard ratio [HR] = 0.45; 95% confidence interval [CI], 0.33–0.62) and lymphoma-related survival (HR = 0.58; 95% CI, 0.38–0.88). However, those patients who received R-CHOP also had higher rates of hospitalization compared with their younger counterparts (74.9% vs 66.2%; P = .0001).

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Content